Search results for " Estimated glomerular filtration rate"

showing 3 items of 3 documents

Effects of sleep apnea and kidney dysfunction on objective sleep quality in nondialyzed patients with chronic kidney disease: an ESADA study

2020

Study Objectives: Patients with chronic kidney disease (CKD) often report poor sleep quality, but they commonly exhibit OSA. The aim of this study was to evaluate the influence of OSA severity and of estimated glomerular filtration rate impairment on objective sleep quality in nondialyzed patients with CKD, defined as an estimated glomerular filtration rate <60 mL/min/1.73m2. Methods: Polysomnographic sleep characteristics were compared between patients with (n = 430) and without CKD (n = 6,639) in the European Sleep Apnea Database cohort. Comparisons were repeated in 375 patients with CKD and 375 control patients without CKD matched for sleep center, age, sex, and AHI, and in 310 matche…

Chronic kidney disease ; Estimated glomerular filtration rate ; Sleep apnea ; Sleep qualitysleep quality.Pulmonary and Respiratory Medicinemedicine.medical_specialtyRenal functionSettore MED/10 - Malattie Dell'Apparato RespiratorioKidneyurologic and male genital diseases03 medical and health sciencesSleep Apnea Syndromes0302 clinical medicinestomatognathic systemChronic kidney diseaseInternal medicineHumansMedicineEstimated glomerular filtration rateRenal Insufficiency ChronicSleep Apnea ObstructiveSleep qualitybusiness.industrySleep apneaKidney dysfunctionSleep apneaSleep qualitymedicine.diseaseScientific Investigationsfemale genital diseases and pregnancy complicationsnervous system diseasesrespiratory tract diseasesPoor sleep030228 respiratory systemNeurologyHuman medicineNeurology (clinical)Sleepbusiness030217 neurology & neurosurgeryKidney diseaseJournal of Clinical Sleep Medicine
researchProduct

Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: A role for organ damage markers

2012

BACKGROUND: Cardiovascular risk assessment in the clinical practice is mostly based on risk charts, such as Framingham risk score and Systemic Coronary Risk Estimation (SCORE). These enable clinicians to estimate the impact of cardiovascular risk factors and assess individual cardiovascular risk profile. Risk charts, however, do not take into account subclinical organ damage, which exerts independent influence on risk and may amplify the estimated risk profile. Inclusion of organ damage markers in the assessment may thus contribute to improve this process. OBJECTIVE: Our aim was to evaluate the influence of implementation of SCORE charts with widely available indexes of organ damage, with t…

cardiovascular riskmedicine.medical_specialtyestimated glomerular filtration ratemicroalbuminuriaPhysiologyCardiovascular risk organ damage markersCoronary DiseaseLeft ventricular hypertrophyRisk Assessmentmetabolic syndromecardiovascular risk; estimated glomerular filtration rate; left ventricular hypertrophy; metabolic syndrome; microalbuminuria; prevention; score; target organ damagepreventiontarget organ damageSCOREInternal MedicineMedicineHumansAlbuminuriaRisk factorIntensive care medicineEstimationFramingham Risk Scorebusiness.industryMetabolic Syndrome XBiomarkermedicine.diseaseSurgeryleft ventricular hypertrophyAlbuminuriaMicroalbuminuriamedicine.symptomMetabolic syndromebusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersGlomerular Filtration RateHuman
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct